Venezia: E Raise, F Ebo ,
President of the SHCS, Centre Hospitalier Universitaire Vaudois, CH-1011-Lausanne), H. Furrer (Chairman of the Clinical and Laboratory Committee, Chairman of the Scientific Board ,
A.I. van Sighem (senior researcher), C. Smit (epidemiologist), F. de Wolf (director) Treating physicians (*Site coordinating physicians) Academisch Medisch Centrum bij de Universiteit van Amsterdam -Amsterdam: Dr, J.M. Prins*, Dr. J. Branger, Dr. J.K.M ,
URL : https://hal.archives-ouvertes.fr/hal-00420991
Academisch Ziekenhuis Maastricht - Maastricht Catharina Ziekenhuis -Eindhoven: Dr ,
Kennemer Gasthuis -Haarlem: Prof, Prof. dr. P.J. van den Broek ,
Medisch Centrum Leeuwarden -Leeuwarden Onze Lieve Vrouwe Gasthuis - Amsterdam, Prof. dr. K. Brinkman*, Drs. G.E.L. van den Berk, Dr. W.L. Blok, Dr. P.H.J ,
Elisabeth Ziekenhuis -Tilburg: Dr, J.R. Juttmann*, Dr. C ,
Lucas Andreas Ziekenhuis -Amsterdam: Dr ,
Radboud -Nijmegen: Dr, P.P. Koopmans* ,
Onze Lieve Vrouwe Gasthuis -Amsterdam Slotervaart Ziekenhuis - Amsterdam, Prof. dr. B. Berkhout, Dr. S. Jurriaans. CLB Stichting Sanquin Bloedvoorziening -Amsterdam: Dr. Th. Cuijpers ,
Laboratorium voor de Volksgezondheid in Friesland -Leeuwarden: Dr Leids Universitair Medisch Centrum -Leiden, Universitair Medisch Centrum St. Radboud -Nijmegen: Prof. dr. J.M.D. Galama, Dr. W.J.G. Melchers, Dr. Verduyn- Lunel. Erasmus MC -Rotterdam: Dr. G.J.J. van Doornum, Dr. H.G.M. Niesters, Prof. dr ,
Hungary (D Banhegyi) Szent Lásló Hospital, Budapest. Ireland (F Mulcahy) St. James's Hospital, Dublin. Israel (I Yust), Medizinische Hochschule Hannover. Greece (J Kosmidis) Athens General Hospital Rambam Medical Center ,
Osrodek Diagnostyki i Terapii AIDS, Chorzow; H Trocha, Medical University, Gdansk. Portugal (F Antunes) E Valadas, Hospital Santa Maria, Lisbon; K Mansinho, Hospital de Egas Moniz, Lisbon; F Matez, Hospital Curry Cabral The Institute for Infectious and Tropical Diseases, Belgrade. Slovakia (M Mokrá?) D Staneková, Dérer Hospital, Lisbon. Romania (D Duiculescu) Spitalul de Boli Infectioase si Tropicale: Dr. Victor Babes, Bucarest; A Streinu-Cercel, Institute of Infectious Diseases Medical Academy Botkin Hospital Bratislava. Spain (J González-Lahoz) Hospital Carlos III Hospital Germans Trias i Pujol ,
Steering committee J ,
Hospital Son Dureta de Mallorca) Scientific committee A ,
Hospital Son Dureta de Mallorca) F ,
Corporació Parc Taulí de Sabadell); L. Force, Hospital de Mataró ,
Hospital de Vic); A. Masabeu (Hospital de Palamós); I García, Hospital General d´Hospitaletd´Hospitalet ,
Hospital Alt Penedès de Vilafranca ,
French Hospital Database, Lyon Primary Infection cohort (Philippe Vanhems), SEROCO cohort ,
Ruslan Malyuta) United Kingdom Edinburgh Hospital cohort, Ukraine Perinatal Prevention of AIDS Initiative Health Protection Agency Royal Free haemophilia cohort (Caroline Sabin, Christine Lee), UK Register of HIV Seroconverters (Kholoud Porter ,
Hazard ratios comparing deferring cART to a lower CD4 range with starting in a higher CD4 range, among patients with presumed transmission via IDU ,
Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study, BMJ, vol.315, issue.7117, pp.3151194-3151203, 1997. ,
DOI : 10.1136/bmj.315.7117.1194
Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection, New England Journal of Medicine, vol.338, issue.13, pp.853-908, 1998. ,
DOI : 10.1056/NEJM199803263381301
A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less, New England Journal of Medicine, vol.337, issue.11, pp.725-758, 1997. ,
DOI : 10.1056/NEJM199709113371101
Effect of Highly Active Antiretroviral Therapy on Time to Acquired Immunodeficiency Syndrome or Death using Marginal Structural Models, American Journal of Epidemiology, vol.158, issue.7, pp.687-94, 2003. ,
DOI : 10.1093/aje/kwg206
Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study, The Lancet, vol.366, issue.9483, pp.378-84, 2005. ,
DOI : 10.1016/S0140-6736(05)67022-5
CD4+ count-guided interruption of antiretroviral treatment, N Engl J Med, vol.355, issue.22, pp.2283-96, 2006. ,
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study, J Infect Dis, vol.197, issue.8, pp.1133-1177, 2008. ,
Rates of Disease Progression by Baseline CD4 Cell Count and Viral Load After Initiating Triple-Drug Therapy, JAMA, vol.286, issue.20, pp.2568-77, 2001. ,
DOI : 10.1001/jama.286.20.2568
HIV Viral Load Response to Antiretroviral Therapy According to the Baseline CD4 Cell Count and Viral Load, JAMA, vol.286, issue.20, pp.2560-2567, 2001. ,
DOI : 10.1001/jama.286.20.2560
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies, The Lancet, vol.360, issue.9327, pp.119-148, 2002. ,
DOI : 10.1016/S0140-6736(02)09411-4
Initiating Antiretroviral Therapy During HIV Infection, JAMA, vol.286, issue.20, pp.2597-2606, 2001. ,
DOI : 10.1001/jama.286.20.2597
Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies, Statistics in Medicine, vol.157, issue.21, pp.3351-63, 2004. ,
DOI : 10.1002/sim.1579
Pre-AIDS mortality from natural causes associated with HIV disease progression, AIDS, vol.11, issue.14, pp.1747-56, 1997. ,
DOI : 10.1097/00002030-199714000-00012
Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users, CMAJ, vol.169, issue.7, pp.656-61, 2003. ,
Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients, J Acquir Immune Defic Syndr, vol.46, issue.5, pp.607-622, 2007. ,
THE MULTICENTER AIDS COHORT STUDY: RATIONALE, ORGANIZATION, AND SELECTED CHARACTERISTICS OF THE PARTICIPANTS, American Journal of Epidemiology, vol.126, issue.2, pp.310-318, 1987. ,
DOI : 10.1093/aje/126.2.310
The Swiss HIV Cohort Study: Rationale, organization and selected baseline characteristics, Sozial- und Pr??ventivmedizin, vol.340, issue.6, pp.387-94, 1994. ,
DOI : 10.1007/BF01299670
Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor, AIDS, vol.14, issue.2, pp.141-150, 2000. ,
DOI : 10.1097/00002030-200001280-00009
Modeling Changes in CD4-positive T-Lymphocyte Counts after the Start of Highly Active Antiretroviral Therapy and the Relation with Risk of Opportunistic Infections The Aquitaine Cohort, 1996???1997, American Journal of Epidemiology, vol.153, issue.4, pp.386-93, 1996. ,
DOI : 10.1093/aje/153.4.386
Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men, J Infect Dis, vol.158, issue.3, pp.615-637, 1988. ,
Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor, AIDS, vol.12, issue.16, pp.2161-2168, 1998. ,
DOI : 10.1097/00002030-199816000-00011
Determinants of survival following HIV-1 seroconversion after the introduction of HAART, Lancet, vol.362, issue.9392, pp.1267-74, 2003. ,
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies, The Lancet, vol.360, issue.9327, pp.119-148, 2002. ,
DOI : 10.1016/S0140-6736(02)09411-4
Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy, Statistics in Medicine, vol.23, issue.15, pp.2375-98, 2003. ,
DOI : 10.1002/sim.1825
Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data, Journal of Clinical Epidemiology, vol.58, issue.10, pp.1033-1074, 2005. ,
DOI : 10.1016/j.jclinepi.2005.02.015
CD4 Cell Counts of 800 Cells/mm3 or Greater After 7 Years of Highly Active Antiretroviral Therapy Are Feasible in Most Patients Starting With 350 Cells/mm3 or Greater, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.45, issue.2, pp.183-92, 2007. ,
DOI : 10.1097/QAI.0b013e31804d685b
Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients, AIDS, vol.14, issue.5, pp.499-507, 2000. ,
Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy, AIDS, vol.11, issue.14, pp.1731-1739, 1997. ,
DOI : 10.1097/00002030-199714000-00010
Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients, AIDS, vol.11, issue.14, pp.113-116, 1997. ,
DOI : 10.1097/00002030-199714000-00001
Zidovudine and Stavudine Sequencing in HIV Treatment Planning: Findings From the CHORUS HIV Cohort, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.26, issue.1, pp.72-81, 2001. ,
DOI : 10.1097/00126334-200101010-00011
Distribution of Health Care Expenditures for HIV-Infected Patients, Clinical Infectious Diseases, vol.42, issue.7, pp.1003-1013, 2006. ,
DOI : 10.1086/500453
Development and Verification of a ???Virtual??? Cohort Using the National VA Health Information System, Medical Care, vol.44, issue.Suppl 2, pp.25-30, 2006. ,
DOI : 10.1097/01.mlr.0000223670.00890.74
The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997, AIDS, vol.13, issue.10, pp.1255-61, 1999. ,
DOI : 10.1097/00002030-199907090-00016
Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens, CMAJ, vol.160, issue.5, pp.659-65, 1999. ,
Caracter??sticas clinicoepidemiol??gicas y tendencias en el tratamiento antirretroviral de una cohorte de pacientes con infecci??n por el virus de la inmunodeficiencia humana. Cohorte PISCIS, Medicina Cl??nica, vol.124, issue.14, pp.525-556, 2005. ,
DOI : 10.1157/13073938
Regional differences in use of antiretroviral agents and primary prophylaxis, p.3122 ,
EuroSIDA Study Group, J Acquir.Immune.Defic.Syndr.Hum.Retrovirol, vol.16, issue.3, pp.153-60, 1997. ,
Multiple Imputation for Nonresponse in Surveys, 1987. ,
DOI : 10.1002/9780470316696
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies, AIDS, vol.21, issue.9, pp.1185-97, 2007. ,
Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4^+ Cell Strata, Annals of Internal Medicine, vol.138, issue.8, pp.620-626, 2003. ,
DOI : 10.7326/0003-4819-138-8-200304150-00007
: Disease Progression, Treatment Durability, and Drug Toxicity, Clinical Infectious Diseases, vol.36, issue.6, pp.812-817, 2003. ,
DOI : 10.1086/367934
Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain), J Acquir Immune Defic Syndr, vol.47, issue.2, pp.212-232, 2008. ,
Treatment for Adult HIV Infection, JAMA, vol.296, issue.7, pp.827-870, 2006. ,
DOI : 10.1001/jama.296.7.827
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries, Lancet, vol.367, issue.9513, pp.817-841, 2006. ,
Recommendations on Prophylaxis and Therapy for Disseminated Mycobacterium avium Complex Disease in Patients Infected with the Human Immunodeficiency Virus, New England Journal of Medicine, vol.329, issue.12, pp.898-904, 1993. ,
DOI : 10.1056/NEJM199309163291228
Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection, Lancet, vol.343, pp.871-81, 1994. ,
Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals, Lancet, vol.348, issue.9023, pp.283-91, 1996. ,
An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002, J Acquir Immune Defic Syndr, vol.39, issue.2, pp.195-203, 2005. ,
Changes Over Time in Risk of Initial Virological Failure of Combination Antiretroviral Therapy, Archives of Internal Medicine, vol.166, issue.5, pp.521-529, 1996. ,
DOI : 10.1001/archinte.166.5.521
When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients, The Lancet Infectious Diseases, vol.5, issue.7, pp.407-421, 2005. ,
DOI : 10.1016/S1473-3099(05)70162-6
When should antiretroviral therapy for HIV be started?, BMJ, vol.334, issue.7584, pp.76-84, 2007. ,
DOI : 10.1136/bmj.39064.406389.94
Latent reservoirs of HIV: Obstacles to the eradication of virus, Proceedings of the National Academy of Sciences, vol.96, issue.20, pp.10958-61, 1999. ,
DOI : 10.1073/pnas.96.20.10958
Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study, The Lancet, vol.353, issue.9170, pp.2093-2102, 1999. ,
DOI : 10.1016/S0140-6736(98)08468-2
Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults, New England Journal of Medicine, vol.352, issue.1, pp.48-62, 2005. ,
DOI : 10.1056/NEJMra041811
Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral na??ve patients, AIDS, vol.14, issue.5, pp.499-507, 2000. ,
DOI : 10.1097/00002030-200003310-00005
Combination antiretroviral therapy and the risk of myocardial infarction, N.Engl.J.Med, vol.349, issue.21, pp.1993-2003, 2003. ,
Class of antiretroviral drugs and the risk of myocardial infarction, N.Engl.J.Med, vol.356, issue.17, pp.1723-1758, 2007. ,
Antiretroviral-therapy-associated lipoatrophy: current status and future directions, Sexual Health, vol.2, issue.3, pp.153-63, 2005. ,
DOI : 10.1071/SH04058
Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study, AIDS, vol.16, issue.12, pp.1663-71, 2002. ,
DOI : 10.1097/00002030-200208160-00012
The role of HIV in serious diseases other than AIDS, AIDS, vol.22, issue.18, pp.2409-2427, 2008. ,
DOI : 10.1097/QAD.0b013e3283174636
When To Start Therapy for HIV Infection: A Swinging Pendulum in Search of Data, Annals of Internal Medicine, vol.138, issue.8, pp.680-681, 2003. ,
DOI : 10.7326/0003-4819-138-8-200304150-00018
Therapy for Early HIV Infection: How Far Back Should the Pendulum Swing?, The Journal of Infectious Diseases, vol.190, issue.6, pp.1043-1048, 2004. ,
DOI : 10.1086/422852
Time to Hit HIV, Early and Hard, New England Journal of Medicine, vol.333, issue.7, pp.450-451, 1995. ,
DOI : 10.1056/NEJM199508173330710
The Case for Conservative Management of Early HIV Disease, JAMA, vol.280, issue.1, pp.93-98, 1998. ,
DOI : 10.1001/jama.280.1.93
The Case for Earlier Treatment of HIV Infection, Clinical Infectious Diseases, vol.39, issue.11, pp.1699-704, 2004. ,
DOI : 10.1086/425743
Antiretroviral Treatment of Adult HIV Infection, JAMA, vol.300, issue.5, pp.555-70, 2008. ,
DOI : 10.1001/jama.300.5.555
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults, HIV Medicine, vol.9, issue.2, pp.65-71, 2008. ,
DOI : 10.1086/426589
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice, AIDS, vol.19, issue.5, pp.487-94, 2005. ,
Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution, Statistics in Medicine, vol.24, issue.23, pp.4352-74, 2007. ,
DOI : 10.1002/sim.2836